United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - octreotide acetate - solution for injection - 500microgram/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - octreotide acetate 11.2mg equivalent to octreotide 10 mg;   - powder for injection with diluent - 10 mg - active: octreotide acetate 11.2mg equivalent to octreotide 10 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer 188 water for injection - treatment of patients with acromegaly; in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-enteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas/zollinger-ellison syndrome - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - octreotide acetate 22.4mg equivalent to octreotide 20 mg;   - powder for injection with diluent - 20 mg - active: octreotide acetate 22.4mg equivalent to octreotide 20 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer 188 water for injection - treatment of patients with acromegaly; in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-enteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas/zollinger-ellison syndrome - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - octreotide acetate 33.6mg equivalent to octreotide 30 mg;   - powder for injection with diluent - 30 mg - active: octreotide acetate 33.6mg equivalent to octreotide 30 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer 188 water for injection - treatment of patients with acromegaly; in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-enteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas/zollinger-ellison syndrome - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - octreotide -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharmaceuticals industries australia pty ltd - octreotide -

Israel - English - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - English - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.05 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - English - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.5 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome. vipomas . glucagonomas . gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - English - Ministry of Health

novartis israel ltd - octreotide - powder and solvent for suspension for injection - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.